Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.54 |
| ▸ | HTR3B | O95264 | 3/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.54 |
| ▸ | HTR5A | P47898 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098142 | 0.94 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6100681 | 0.84 | HTR3A (0.53) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6101655 | 0.83 | HTR3A (0.52) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6098440 | 0.82 | HTR3A (0.53) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6101425 | 0.82 | CHRNA7 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6101418 | 0.82 | CHRNA7 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6100858 | 0.81 | HTR3A (0.52) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6098212 | 0.81 | CHRNA7 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6099896 | 0.80 | CHRNA7 (0.50) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6099745 | 0.80 | HTR3A (0.49) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HTR3A 3325/4885HTR3E 4210/4885HTR3B 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.